A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector & Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA)

Trial Profile

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector & Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Bevacizumab; Lomustine; Temozolomide; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Toca 5
  • Sponsors Tocagen
  • Most Recent Events

    • 23 Feb 2017 According to a Tocagen media release, top-line results from the Phase 2 portion are anticipated in the first half of 2018.
    • 23 Feb 2017 According to a Tocagen media release, company has completed patient enrolment in the Phase 2 portion of the study.
    • 08 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top